Clinical Trials Logo

Clinical Trial Summary

Investigation of systemic catechin exposure following topically administered Veregen® 15% ointment in patients with external genital and perianal warts and following oral intake of a standardized green tea beverage in healthy subjects.

Pharmacokinetic parameters for the main catechin EGCg used as a marker of overall catechin exposure following dermal administration in the patient group will only be calculated if sufficiently consistent data can be obtained e.g. sufficient plasma catechin concentrations to pharmacokinetically evaluate plasma profiles for plasma catechin concentrations.

If applicable, a safety margin for ointment use might need to be established with respect to intolerable systemic exposures of catechins following application of Veregen® ointment.

In treatment arm 1, patients with anogenital warts will apply Veregen® 15% ointment 250 mg three times daily: in the morning, at midday, and in the evening on the defined anogenital administration area (total dose of 750 mg/d) for one week .

In treatment arm 2, healthy subjects will ingest 500 mL commercially available green tea beverage ("Lipton® Green Limone" distributed by PepsiCo Deutschland GmbH, Neu-Isenburg, Germany), three times daily in the morning, at midday, and in the evening (total dose of 1500 mL/d) for one week.

Plasma samples will be collected to aim for a complete pharmacokinetic assessment (over 24 hours) on Days 1 and 2 at Visit 2 and on Days 7 and 8 at Visit 3 (one week after first dosing).

To avoid any influence on overall systemic catechin exposure deriving from any other source than Veregen® or Lipton Green Tea, all subjects participating in the trial (patients and healthy volunteers) will be asked to follow a defined diet abstaining from food or beverages known to containing catechins (a list of all prohibited and allowed foods and beverages will be provided to all subjects).

For concomitant medication, only paracetamol and oral contraceptives are allowed.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01490008
Study type Interventional
Source MediGene
Contact
Status Completed
Phase Phase 1
Start date December 2011
Completion date March 2012

See also
  Status Clinical Trial Phase
Completed NCT02015260 - A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts Phase 2
Completed NCT05156541 - Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts Phase 3
Completed NCT01532102 - Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts Phase 1/Phase 2
Completed NCT02276521 - Evaluation of Long Term Immunity Following HPV Vaccination Phase 2/Phase 3
Completed NCT02377999 - Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts Phase 2
Completed NCT01387412 - The Role of Genital Warts in HIV Acquisition in Peru N/A